<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34823917</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-8111</ISSN><JournalIssue CitedMedium="Internet"><Volume>177</Volume><PubDate><Year>2022</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Neuroscience research</Title><ISOAbbreviation>Neurosci Res</ISOAbbreviation></Journal><ArticleTitle>Decreased plasma ghrelin in male ALS patients is associated with poor prognosis.</ArticleTitle><Pagination><StartPage>111</StartPage><EndPage>117</EndPage><MedlinePgn>111-117</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neures.2021.11.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0168-0102(21)00237-6</ELocationID><Abstract><AbstractText>Physiological changes including altered nutritional status influence disease progression and survival in patients with amyotrophic lateral sclerosis (ALS). Ghrelin affects the nutritional status by regulating appetite and energy expenditure, and also has neuroprotective effects. To investigate the association between ghrelin and ALS prognosis, we analyzed plasma acylated-ghrelin levels in 33 patients with ALS. Compared among ALS patients, male had lower plasma ghrelin levels than female, although disease specificity is unknown. ALS patients, especially male ALS patients, with low plasma ghrelin levels (&lt;15 fmol/mL) had significantly shorter post-examination survival times than those with high plasma ghrelin levels (&#x2265;15 fmol/mL). Univariate and multivariate analyses revealed a significant effect of ghrelin levels on post-examination survival. Immunohistochemical study of autopsied stomach samples from 8 of 33 patients revealed that the population of ghrelin-positive cells tended to be reduced in the low-plasma ghrelin group than in the high-plasma ghrelin group. Our findings suggest that ghrelin levels are an independent predictor of survival in ALS, especially male ALS patients, and the ghrelin-positive cells may decrease in ALS with low plasma ghrelin. Thus, reduced ghrelin secretion may be associated with poor prognosis among patients with ALS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nagaoka</LastName><ForeName>Utako</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tokyo Metropolitan Neurological Hospital, Tokyo, 183-0042, Japan. Electronic address: utako_nagaoka@tmhp.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimizu</LastName><ForeName>Toshio</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tokyo Metropolitan Neurological Hospital, Tokyo, 183-0042, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uchihara</LastName><ForeName>Toshiki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory of Structural Neuropathology, Tokyo Metropolitan Institute of Medical Science, Tokyo, 156-8506, Japan; Department of Neurology, Nitobe Memorial Nakano General Hospital, Tokyo, 164-8607, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Komori</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory Medicine and Pathology, Tokyo Metropolitan Neurological Hospital, Tokyo, 183-0042, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hosoda</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Regenerative Medicine and Tissue Engineering, National Cerebral and Cardiovascular Center Research Institute, Osaka, 564-8565, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Kazushi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tokyo Metropolitan Neurological Hospital, Tokyo, 183-0042, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Neurosci Res</MedlineTA><NlmUniqueID>8500749</NlmUniqueID><ISSNLinking>0168-0102</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054439">Ghrelin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054439" MajorTopicYN="N">Ghrelin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012727" MajorTopicYN="N">Sex Characteristics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Double-immunofluorescent study</Keyword><Keyword MajorTopicYN="N">Energy expenditure</Keyword><Keyword MajorTopicYN="N">Ghrelin</Keyword><Keyword MajorTopicYN="N">Prognosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>26</Day><Hour>5</Hour><Minute>48</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34823917</ArticleId><ArticleId IdType="doi">10.1016/j.neures.2021.11.003</ArticleId><ArticleId IdType="pii">S0168-0102(21)00237-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>